Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism

9 Aug 2021

Abstract excerpt

Abstract The implementation of applied engineering principles to create synthetic biological systems promises to revolutionize medicine, but application of fundamentally redesigned organisms has thus far not impacted practical drug development. Here we utilize an engineered microbial organism with a six-letter semi-synthetic DNA code to generate a library of site-specific, click chemistry compatible amino acid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Research and Treatments
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34373459
DOI: 10.1038/s41467-021-24987-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organismPMID 34373459Read ↗

Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic BiologySemantic proximity Read ↗

Microbial Systems Enhancing CAR-Based Therapies: A Synthetic Biology Paradigm for Next-Generation Cancer ImmunotherapySemantic proximity Read ↗

Potent antitumor activity of a designed interleukin-21 mimicSemantic proximity Read ↗

Synthetic Hybrid Receptors for Safer and Programmable T Cell TherapySemantic proximity Read ↗

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protectionSemantic proximity Read ↗

Directed disruption of IL2 aggregation sites produces designer biologics with enhanced specificity coupled to improved production capacitySemantic proximity Read ↗

In vitro and in vivo evaluation of chemically synthesized, receptor-biased interleukin-4 and photocaged variantsSemantic proximity Read ↗

Engineered Microbes Transforming Immune Modulation Across Cancer, Autoimmunity, and InfectionSemantic proximity Read ↗

Rational design of chemically responsive cytokines for cancer immunotherapySemantic proximity Read ↗

In Situ Synthesis of an Immune-Checkpoint Blocker from Engineered Bacteria Elicits a Potent Antitumor ResponseSemantic proximity Read ↗

The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8+ T lymphocyte/Treg cell balance.Semantic proximity Read ↗

New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.